C. Paul-papin, 2 rue Moll, 49933 Angers cedex 9, France. 2 Centre Hospitalier, p.76600, 19312.

L. Havre and B. France, 14 07 Caen Cedex 5, France. 5 Clinique Pasteur, 45 avenue de Lombez, BP 27617, 31076 Toulouse Cedex 3, France. 6 Groupe Hospitalier Saint-André, 1 rue Jean Burguet

T. Cedex and F. , 10 Centre Hospitalier Universitaire, 4 rue Larrey, p.49933

T. Rich, J. Skibber, J. Ajani, D. Buchholz, K. Cleary et al., Preoperative infusional chemoradiation therapy for Stage T3 rectal cancer, International Journal of Radiation Oncology*Biology*Physics, vol.32, issue.4, pp.1025-1034, 1995.
DOI : 10.1016/0360-3016(95)00020-Y

J. Bosset, V. Magnin, P. Maingon, G. Mantion, E. Pelissier et al., Preoperative radiochemotherapy in rectal cancer:, International Journal of Radiation Oncology*Biology*Physics, vol.46, issue.2, pp.323-330, 2000.
DOI : 10.1016/S0360-3016(99)00411-3

T. Lawrence, J. Tepper, and A. Blackstock, Fluoropyrimidine-radiation interactions in cells and tumors, Seminars in Radiation Oncology, vol.7, issue.4, pp.260-266, 1997.
DOI : 10.1016/S1053-4296(97)80024-0

S. Smalley, J. Benedetti, S. Williamson, J. Robertson, N. Estes et al., Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144, Journal of Clinical Oncology, vol.24, issue.22, pp.3542-3549, 2006.
DOI : 10.1200/JCO.2005.04.9544

M. Borner, P. Schöffski, R. De-wit, F. Caponigro, G. Comella et al., Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin, European Journal of Cancer, vol.38, issue.3, pp.349-58, 2002.
DOI : 10.1016/S0959-8049(01)00371-9

P. Hoff, N. Janjan, E. Saad, J. Skibber, C. Crane et al., Phase I Study of Preoperative Oral Uracil and Tegafur Plus Leucovorin and Radiation Therapy in Rectal Cancer, Journal of Clinical Oncology, vol.18, issue.20, pp.3529-3563, 2000.
DOI : 10.1200/JCO.2000.18.20.3529

A. De-la-torre, S. Ramos, F. Valcárcel, A. Candal, C. Regueiro et al., Phase II study of radiochemotherapy with uft and low-dose oral leucovorin in patients with unresectable rectal cancer, International Journal of Radiation Oncology*Biology*Physics, vol.45, issue.3, pp.629-663, 1999.
DOI : 10.1016/S0360-3016(99)00225-4

A. De-la-torre, M. García-berrocal, F. Arias, A. Mariño, F. Valcárcel et al., Preoperative Chemoradiotherapy for Rectal Cancer: Randomized Trial Comparing Oral Uracil and Tegafur and Oral Leucovorin Vs. Intravenous 5-Fluorouracil and Leucovorin, International Journal of Radiation Oncology*Biology*Physics, vol.70, issue.1, pp.102-112, 2008.
DOI : 10.1016/j.ijrobp.2007.05.068

J. Feliu, J. Calvillo, A. Escribano, J. De-castro, M. Sánchez et al., Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy, Annals of Oncology, vol.13, issue.5, pp.730-736, 2002.
DOI : 10.1093/annonc/mdf116

L. Wang, S. Yang, J. Lin, T. Lin, W. Chan et al., Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer, Journal of Surgical Oncology, vol.20, issue.4, pp.256-64, 2005.
DOI : 10.1002/jso.20168

C. Fernández-martos, J. Aparicio, C. Bosch, M. Torregrosa, J. Campos et al., Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study With 3 Years' Follow-Up, Journal of Clinical Oncology, vol.22, issue.15, pp.3016-3038, 2004.
DOI : 10.1200/JCO.2004.11.124

L. Vestermark, A. Jacobsen, C. Qvortrup, L. Vestermark, A. Jacobsen et al., Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC), Acta Oncologica, vol.45, issue.3, pp.428-461, 2008.
DOI : 10.1016/j.gassur.2006.09.005

Y. Kundel, B. Brenner, Z. Symon, B. Oberman, S. Sadezki et al., A phase II study of oral UFT and leucovorin concurrently with pelvic irradiation as neoadjuvant chemoradiation for rectal cancer, Anticancer Res, vol.27, pp.2877-80, 2007.

J. Giralt, J. Tabernero, B. Navalpotro, J. Capdevila, E. Espin et al., Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: A phase II study, Radiotherapy and Oncology, vol.89, issue.3, pp.263-272, 2008.
DOI : 10.1016/j.radonc.2008.07.010

K. Seck, S. Riemer, R. Kates, T. Ullrich, V. Lutz et al., Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals, Clinical Cancer Research, vol.11, issue.16, pp.5886-92, 2005.
DOI : 10.1158/1078-0432.CCR-04-1784

R. Diasio and M. Johnson, Dihydropyrimidine dehydrogenase: its role in 5- fluorouracil clinical toxicity and tumor resistance, Clin Cancer Res, vol.5, pp.2672-2675, 1999.

M. Saif and R. Diasio, Is Capecitabine Safe in Patients with Gastrointestinal Cancer and Dihydropyrimidine Dehydrogenase Deficiency?, Clinical Colorectal Cancer, vol.5, issue.5, pp.359-62, 2006.
DOI : 10.3816/CCC.2006.n.007

A. Van-kuilenburg, R. Abreu, and A. Van-gennip, Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency, Annals of Clinical Biochemistry, vol.40, issue.1, pp.41-46, 2003.
DOI : 10.1258/000456303321016150

A. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, Reporting results of cancer treatment, Cancer, vol.11, issue.1, pp.207-221, 1981.
DOI : 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6

F. Mornex, J. Pavy, J. Denekamp, and M. Bolla, Syst??me d'??valuation des effets tardifs des radiations sur les tissus normaux: l'??chelle SOMA-LENT, Cancer/Radioth??rapie, vol.1, issue.6, pp.622-68, 1997.
DOI : 10.1016/S1278-3218(97)82941-1

L. Sobin and C. Wittekind, TNM Classification of Malignant Tumours Wiley-Liss, 1997.

S. Meterissian, J. Skibber, T. Rich, L. Roubein, J. Ajani et al., Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma, Annals of Surgical Oncology, vol.37, issue.2, pp.111-117, 1994.
DOI : 10.1007/BF02303553

B. Minsky, A. Cohen, W. Enker, and P. Paty, Sphincter preservation with preoperative radiation therapy and coloanal anastomosis, International Journal of Radiation Oncology*Biology*Physics, vol.31, issue.3, pp.553-562, 1995.
DOI : 10.1016/0360-3016(94)00375-U

A. Morel, M. Boisdron-celle, L. Fey, P. Soulié, M. Craipeau et al., Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance, Molecular Cancer Therapeutics, vol.5, issue.11, pp.2895-904, 2006.
DOI : 10.1158/1535-7163.MCT-06-0327

G. Remaud, M. Boisdron-celle, C. Hameline, A. Morel, and E. Gamelin, An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice, Journal of Chromatography B, vol.823, issue.2, pp.98-107, 2005.
DOI : 10.1016/j.jchromb.2005.05.044

M. Boisdron-celle, G. Remaud, S. Traore, A. Poirier, L. Gamelin et al., 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency, Cancer Letters, vol.249, issue.2, pp.271-82, 2007.
DOI : 10.1016/j.canlet.2006.09.006

E. Gamelin, M. Boisdron-celle, V. Guérin-meyer, R. Delva, A. Lortholary et al., Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage, Journal of Clinical Oncology, vol.17, issue.4, pp.1105-1115, 1999.
DOI : 10.1200/JCO.1999.17.4.1105

R. Simon, Optimal two-stage designs for phase II clinical trials, Controlled Clinical Trials, vol.10, issue.1, pp.1-10, 1989.
DOI : 10.1016/0197-2456(89)90015-9
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.390.7954

D. Kim, K. Jung, T. Kim, D. Kim, H. Chang et al., Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer, International Journal of Radiation Oncology*Biology*Physics, vol.67, issue.2, pp.378-84, 2007.
DOI : 10.1016/j.ijrobp.2006.08.063

J. Dunst, J. Debus, V. Rudat, J. Wulf, W. Budach et al., Pr??operative Radiochemotherapie mit Capecitabin beim lokal fortgeschrittenen Rektumkarzinom: Langzeitergebnisse einer Phase-II-Studie, Strahlentherapie und Onkologie, vol.184, issue.9, pp.450-456, 2008.
DOI : 10.1007/s00066-008-1751-4

R. Sauer, H. Becker, W. Hohenberger, C. Rödel, C. Wittekind et al., German Rectal Cancer Study Group: Preoperative chemoradiotherapy for rectal cancer, N Eng J Med, vol.351, pp.17316-17356, 2004.

F. Calvo, F. Serrano, J. Diaz-gonzález, M. Gomez-espi, E. Lozano et al., Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus Cellier et alfluorouracil and preoperative chemoradiation, BMC Cancer Ann Oncol, vol.11, issue.17, pp.1103-1113, 2006.

D. Ryan, D. Niedzwiecki, D. Hollis, B. Mediema, S. Wadler et al., Phase I/II Study of Preoperative Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Cancer and Leukemia Group B 89901, Journal of Clinical Oncology, vol.24, issue.16, pp.2557-62, 2006.
DOI : 10.1200/JCO.2006.05.6754

D. Sebag-montefiore, R. Glynne-jones, S. Falk, H. Meadows, and T. Maughan, A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study, British Journal of Cancer, vol.336, issue.9, pp.993-1001, 2005.
DOI : 10.1046/j.1365-2168.2002.02169_2.x

N. Janjan, V. Khoo, J. Abbruzzese, R. Pazdur, R. Dubrow et al., Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M

A. Chan, A. Wong, D. Jenken, J. Heine, D. Buie et al., Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.61, issue.3, pp.665-77, 2005.
DOI : 10.1016/j.ijrobp.2004.06.206

S. Mawdsley, R. Glynne-jones, J. Grainger, P. Richman, A. Makris et al., Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.3, pp.745-52, 2005.
DOI : 10.1016/j.ijrobp.2005.03.003

V. Muthusamy and K. Chang, Optimal Methods for Staging Rectal Cancer, Clinical Cancer Research, vol.13, issue.22, pp.6877-84, 2007.
DOI : 10.1158/1078-0432.CCR-07-1137

S. Rasheed, T. Guenther, I. Talbot, P. Mcdonald, J. Northover et al., USPIO ? enhanced rectal cancer specimen MRI: how well does it correlate with node identification at histopathology?, Colorectal Disease, vol.8, issue.8, p.721, 2006.
DOI : 10.1111/j.1463-1318.2006.01102_1.x

J. Gérard, T. Conroy, F. Bonnetain, O. Bouché, O. Chapet et al., Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203, Journal of Clinical Oncology, vol.24, issue.28, pp.4620-4625, 2006.
DOI : 10.1200/JCO.2006.06.7629

J. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon et al., Chemotherapy with Preoperative Radiotherapy in Rectal Cancer, New England Journal of Medicine, vol.355, issue.11, pp.1114-1137, 2006.
DOI : 10.1056/NEJMoa060829
URL : https://hal.archives-ouvertes.fr/hal-00484917

S. Rodríguez-ramírez, A. Uribe, E. Ruiz-garcía, S. Labastida, and P. Luna-pérez, Risk factors for anastomotic leakage after preoperative chemoradiation therapy and low RA with total mesorectal excision for locally advanced rectal cancer, Rev Invest Clin, vol.58, pp.204-214, 2006.

E. Urso, S. Serpentini, S. Pucciarelli, D. Salvo, G. Friso et al., Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer, European Journal of Surgical Oncology (EJSO), vol.32, issue.10, pp.1201-1209, 2006.
DOI : 10.1016/j.ejso.2006.07.003

D. Chen and C. Nirodi, The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage, Clinical Cancer Research, vol.13, issue.22, pp.6555-60, 2007.
DOI : 10.1158/1078-0432.CCR-07-1610

J. Bosset, F. Nguyen, M. Bosset, S. Servagi-vernat, and B. Schipman, Recent advances in the treatment of localized rectal cancer, Current Oncology Reports, vol.23, issue.Suppl3, pp.220-224, 2008.
DOI : 10.1007/s11912-008-0034-7
URL : https://hal.archives-ouvertes.fr/hal-00492559